Tocilizumab biosimilar is under clinical development by Fresenius Kabi SwissBioSim and currently in Pre-Registration for Polyarticular Juvenile Idiopathic Arthritis (PJIA). According to GlobalData, Pre-Registration drugs for Polyarticular Juvenile Idiopathic Arthritis (PJIA) have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Tocilizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tocilizumab biosimilar overview
MSB-11456 is under development for the treatment of systemic sclerosis, moderately to severely active rheumatoid arthritis, juvenile rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. It is an tocilizumab biosimilar. The drug candidate is administered through subcutaneous route. It acts by targeting interleukin 6 receptor.
For a complete picture of Tocilizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.